Candel Therapeutics Inc. (CADL) PT Raised to $25 at Canaccord Genuity
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq rallies as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts CADL Hot Sheet
Price: $8.65 +6.53%
Rating Summary:
13 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 21 | New: 13
Rating Summary:
13 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 21 | New: 13
Join SI Premium – FREE
Canaccord Genuity analyst John Newman raised the price target on Candel Therapeutics Inc. (NASDAQ: CADL) to $25.00 (from $20.00) while maintaining a Buy rating.
You May Also Be Interested In
- Hagerty Inc. (HGTY) PT Raised to $20 at Oppenheimer
- Shopify (SHOP) PT Lowered to $180 at DA Davidson
- Philip Morris (PM) PT Raised to $232 at Stifel
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
